Company Announcements

Albemarle Reports Second-Quarter Results

CHARLOTTE, N.C., Aug. 4, 2021 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB) today announced its results for the second quarter ended June 30, 2021.

Second Quarter 2021 Highlights
(Unless otherwise stated, all percent changes are based on year-over-year comparisons)

  • Net income of $424.6 million, or $3.62 per diluted share, including a gain on the sale of Fine Chemistry Services (FCS) business
  • Adjusted diluted EPS of $0.89, an increase of 4%
  • Net sales of $773.9 million, an increase of 1%; Net sales increased 5% excluding FCS
  • Adjusted EBITDA of $194.6 million, an increase of 5%; Adjusted EBITDA increased 13% excluding FCS
  • Full year 2021 outlook revised to reflect better than expected Lithium performance, lower interest expense and tax rates, offset by higher Bromine raw material costs and supply chain disruptions; guidance updated to reflect sale of FCS
  • Completed the sale of FCS on June 1, 2021, in a cash and stock transaction valued at ~$570 million
  • La Negra III/IV commissioning stage in process, commercial production expected to begin in first half of 2022

"Albemarle delivered another strong quarter, generating $195 million in adjusted EBITDA, driven by continued strength in demand for our Lithium and Bromine products," said Albemarle CEO Kent Masters. "We are focused on executing our accelerated growth strategy. We are in the final stages of two lithium projects which are expected to double our nameplate capacity to about 175,000 metric tons, including La Negra III/IV where construction is complete and commissioning is progressing. We are firmly focused on advancing all our lithium projects to meet customer demand and accelerate profitable growth."

Outlook

The company continues to expect a modest improvement in operating performance compared to full year 2020, assuming continued global economic recovery. Full-year 2021 net sales guidance is improved compared to previous guidance primarily due to increased Lithium sales and improving Catalysts trends offset by reduced expectations for the Bromine business as a result of higher raw material costs and supply chain disruptions.  Revised EBITDA reflects higher net sales offset by higher corporate costs, primarily related to incentive compensation expense and foreign exchange.  Higher EPS and net cash from operations reflects lower interest expense and tax rates.  Net cash from operations is also expected to benefit from timing of working capital changes.  Capital expenditures are trending near the high-end of the range, due to tighter labor markets and COVID-related travel restrictions in Western Australia.  Pro forma revised guidance has been updated to reflect the sale of Albemarle's Fine Chemistry Services (FCS) business to W. R. Grace, which closed on June 1, 2021.


Revised


FCS Adjustment


Pro Forma Revised


FY 2021 Guidance


(Jun 1 - Dec 31, 2021)


FY 2021 Guidance

Net sales

$3.3 - $3.4 billion


$95 - $105 million


$3.2 - $3.3 billion

Adjusted EBITDA

$810 - $860 million


$35 - $45 million


$775 - $815 million

Adjusted EBITDA Margin

24% - 25%




24% - 25%

Adjusted Diluted EPS

$3.60 - $4.00


$0.25 - $0.30


$3.35 - $3.70

Net Cash from Operations

$590 - $690 million


$40 - $45 million


$550 - $650 million

Capital Expenditures

$850 - $950 million


$4 - $8 million


$850 - $950 million

COVID-19 Response

Albemarle's cross-functional Global Response Team continues to meet regularly to address employee health and safety and operational challenges. The company's priority is always the health and well-being of its employees, customers, and communities. The company continues to focus on building in the flexibility needed to adjust for regional differences and changing conditions.  

Second-Quarter Results

In millions, except per share amounts

Q2 2021


Q2 2020


$ Change


% Change

Net sales

$

773.9



$

764.0



$

9.8



1.3

%

Net income attributable to Albemarle Corporation

$

424.6



$

85.6



$

339.0



395.9

%

Adjusted EBITDA(a)

$

194.6



$

185.2



$

9.4



5.1

%

Diluted earnings per share

$

3.62



$

0.80



$

2.82



352.5

%

   Non-operating pension and OPEB items(a)

(0.04)



(0.02)






   Non-recurring and other unusual items(a)

(2.69)



0.07






Adjusted diluted earnings per share(b)

$

0.89



$

0.86



$

0.03



3.5

%



(a)

See Non-GAAP Reconciliations for further details.

(b)

Totals may not add due to rounding.

Net sales of $773.9 million increased by $9.8 million compared to the prior year quarter, primarily driven by an increase in sales from the company's Lithium and Bromine business segments. Excluding the FCS business, net sales for the quarter increased 5% year-over-year.

Adjusted EBITDA of $194.6 million increased by $9.4 million from the prior year quarter based on higher sales and operating margins, partially offset by higher corporate expense primarily related to higher incentive compensation and foreign exchange. Excluding FCS, adjusted EBITDA was 13% higher when compared to the second quarter of 2020. Net income attributable to Albemarle of $424.6 million increased by $339.0 million, benefiting from a $429.4 million ($331.6 million after taxes) gain on the sale of the company's FCS business.  

The effective income tax rate for the second quarter of 2021 was 20.0% compared to 17.5% in the same period of 2020. The difference is largely due to tax expense recorded in the second quarter of 2021 for the gain on the sale of the FCS business. On an adjusted basis, the effective income tax rates were 17.5% and 18.9% for the second quarter of 2021 and 2020, respectively.

Business Segment Results

Lithium

In millions

Q2 2021


Q2 2020


$ Change


% Change

Net Sales

$

320.3



$

283.7



$

36.6



12.9

%

Adjusted EBITDA

$

109.4



$

94.5



$

14.9



15.8

%

Lithium net sales of $320.3 million increased $36.6 million (+13%) primarily driven by higher volumes (+17%) primarily related to accelerated orders under long-term agreements. Pricing in the quarter was slightly lower year over year (-4%) due to lower average pricing for carbonate and technical grade products. Adjusted EBITDA of $109.4 million increased $14.9 million primarily due to increased net sales and the impact of higher spodumene volumes at the Talison joint venture.

Current Trends:  Full-year 2021 volume growth is expected to be in the mid-teens year-over-year due to North American plant restarts, productivity improvements, and tolling. Average realized pricing is expected to increase sequentially but remain flat compared to 2020. Full-year 2021 adjusted EBITDA is expected to grow between 10% and 15% year over year. Full-year 2021 average margin is expected to remain below 35% due to higher lithium costs related to project start-ups and tolling costs partially offset by efficiency improvements.

Albemarle's Wave 2 growth projects continue to progress.  La Negra III/IV is in the commissioning phase and Kemerton I remains on track for construction completion later this year. To mitigate risks related to labor shortages and COVID-19 travel restrictions in Western Australia, the company prioritized completion of Kemerton I, with Kemerton II construction completion now expected by the end of the first quarter 2022. Kemerton I and II are expected to reach commercial production in 2022 following an approximately six month commissioning and qualification period.     

Bromine Specialties

In millions

Q2 2021


Q2 2020


$ Change


% Change

Net Sales

$

279.7



$

232.8



$

47.0



20.2

%

Adjusted EBITDA

$

92.6



$

73.0



$

19.6



26.8

%

Bromine net sales of $279.7 million increased $47.0 million (+20%) with improved pricing (+9%) and volumes (+11%) driven by higher demand across the portfolio.  Adjusted EBITDA of $92.6 million increased $19.6 million due to higher net sales. Cost savings initiatives and higher pricing helped offset raw materials cost increases.    

Current Trends:  The company expects full-year 2021 adjusted EBITDA growth in the mid-single digits year-over-year, below previous outlook primarily due to a force majeure declaration by our chlorine supplier in the U.S. The company continues to see strength in certain end markets, including electronics, and building and construction. Volumes are also expected to be lower in the second half due to inventory drawdown and reduced production related to the U.S. Gulf Coast winter storms in the first quarter of 2021. Cost savings and higher pricing partially offset inflation in raw materials and freight.   

Catalysts

In millions

Q2 2021


Q2 2020


$ Change


% Change

Net Sales

$

148.3



$

197.1



$

(48.7)



(24.7)

%

Adjusted EBITDA

$

21.2



$

22.8



$

(1.6)



(7.1)

%

Catalysts net sales of $148.3 million decreased $48.7 million (-25%) compared to the previous year, primarily due to lower volumes (-25%) while pricing was flat. Clean Fuels Technologies (CFT) volumes decreased due to timing of shipments. Fluid Catalytic Cracking (FCC) volumes were down slightly versus prior year, as a change in order patterns from a large North American customer offset generally higher FCC demand.  Performance Catalyst Solutions (PCS) results improved due to product mix. Adjusted EBITDA of $21.2 million declined $1.6 million mostly due to lower sales. Also, second quarter 2020 results were understated by $12.0 million due to an out-of-period correction to cost of goods sold for inventory values.

Current Trends:   The company continues to expect full-year 2021 adjusted EBITDA to decline by between 30% and 40%.  Market conditions are improving, but results are expected to be down from prior year primarily due to the impact of the U.S. Gulf Coast winter storm, product mix, and the previously disclosed change in order patterns from a large North American customer.

All Other

In millions

Q2 2021


Q2 2020


$ Change


% Change

Net Sales

$

25.5



$

50.5



$

(25.0)



(49.6)

%

Adjusted EBITDA

$

8.4



$

18.6



$

(10.2)



(54.9)

%

Other operations represents the company's recently sold FCS business. FCS net sales of $25.5 million declined $25.0 million and adjusted EBITDA of $8.4 million declined $10.2 million. Second-quarter 2021 results include only two months of performance following the sale of FCS on June 1, 2021. Albemarle recorded a gain of $429.4 million ($331.6 million after taxes) related to the sale of the FCS business.

Balance Sheet and Liquidity

As of June 30, 2021, Albemarle had estimated liquidity of approximately $2.2 billion, including $823.6 million of cash and equivalents, the full $1.0 billion available under the company's revolver, $270.0 million remaining under its delayed draw term loan and $132.0 million on other available credit lines. Total debt was $2.0 billion, representing net debt to adjusted EBITDA of approximately 1.5 times.

Cash Flow and Capital Deployment

Cash from operations for the six months ended June 30, 2021, of $385.9 million increased $177.9 million versus the prior year driven by working capital inflows and higher revenues in the company's Lithium and Bromine segments. Capital expenditures of $396.9 million decreased by approximately $22.0 million versus the prior year as the company nears completion of its Wave 2 Lithium expansion projects.

Albemarle's primary capital allocation priorities are to grow profitably, fund its dividend, and maintain its financial flexibility and our Investment Grade credit rating. 

In May, the board declared a quarterly dividend of $0.39 per share, an increase over the quarterly dividend paid in 2020. This is Albemarle's 27th consecutive year of dividend increases. The share repurchase authorization remains in place; however, the company has no near-term plans to execute share buybacks.

Earnings Call

Date:

Thursday, August 5, 2021

Time:

9:00 AM Eastern time

Dial-in (U.S.):

844-347-1034

Dial-in (International):

209-905-5910

Passcode:

6747789

The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com.

About Albemarle

Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We think beyond business-as-usual to power the potential of companies in many of the world's largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

We regularly post information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves.

Forward-Looking Statements

Some of the information presented in this press release, the conference call and discussions that follow, including, without limitation, information related to the timing of active and proposed projects, product development, production capacity, committed volumes, market trends, pricing, financial flexibility, expected growth, anticipated return on opportunities, earnings and demand for our products, input costs, productivity improvements, surcharges, tax rates, stock repurchases, dividends, cash flow generation, costs and cost synergies, capital projects, future acquisition and divestiture transactions, expected benefits from proposed transactions, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed. Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory actions, proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our most recent Annual Report on Form 10-K any subsequently filed Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

 

Albemarle Corporation and Subsidiaries
Consolidated Statements of Income
(In Thousands Except Per Share Amounts) (Unaudited)


Three Months Ended


Six Months Ended


June 30,


June 30,


2021


2020


2021


2020

Net sales

$

773,896



$

764,049



$

1,603,187



$

1,502,894


Cost of goods sold

525,479



530,690



1,091,083



1,027,517


Gross profit

248,417



233,359



512,104



475,377


Selling, general and administrative expenses

121,516



106,949



214,703



208,826


Research and development expenses

13,976



14,210



28,612



30,307


Gain on sale of business

(429,408)





(429,408)




Operating profit

542,333



112,200



698,197



236,244


Interest and financing expenses

(7,152)



(17,852)



(51,034)



(34,737)


Other income (expense), net

14



(6,273)



11,326



2,041


Income before income taxes and equity in net income of unconsolidated investments

535,195



88,075



658,489



203,548


Income tax expense

106,985



15,431



129,092



33,873


Income before equity in net income of unconsolidated investments

428,210



72,644



529,397



169,675


Equity in net income of unconsolidated investments (net of tax)

17,998



31,114



34,509



57,718


Net income

446,208



103,758



563,906



227,393


Net income attributable to noncontrolling interests

(21,608)



(18,134)



(43,629)



(34,565)


Net income attributable to Albemarle Corporation

$

424,600



$

85,624



$

520,277



$

192,828


Basic earnings per share

$

3.63



$

0.81



$

4.54



$

1.81


Diluted earnings per share

$

3.62



$

0.80



$

4.51



$

1.81










Weighted-average common shares outstanding – basic

116,809



106,329



114,700



106,278


Weighted-average common shares outstanding – diluted

117,436



106,535



115,383



106,524


 

Albemarle Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In Thousands) (Unaudited)


June 30,


December 31,


2021


2020

ASSETS




Current assets:




Cash and cash equivalents

$

823,572



$

746,724


Trade accounts receivable

455,222



530,838


Other accounts receivable

58,256



61,958


Inventories

732,563



750,237


Other current assets

81,741



116,427


Total current assets

2,151,354



2,206,184


Property, plant and equipment

7,596,684



7,427,641


Less accumulated depreciation and amortization

2,086,085



2,073,016


Net property, plant and equipment

5,510,599



5,354,625


Investments

907,080



656,244


Other assets

256,081



219,268


Goodwill

1,640,720



1,665,520


Other intangibles, net of amortization

331,092



349,105


Total assets

$

10,796,926



$

10,450,946


LIABILITIES AND EQUITY




Current liabilities:




Accounts payable

$

535,153



$

483,221


Accrued expenses

317,954



440,763


Current portion of long-term debt

623



804,677


Dividends payable

45,428



40,937


Income taxes payable

85,770



32,251


Total current liabilities

984,928



1,801,849


Long-term debt

2,043,794



2,767,381


Postretirement benefits

47,371



48,075


Pension benefits

309,712



340,818


Other noncurrent liabilities

616,912



629,377


Deferred income taxes

428,438



394,852


Commitments and contingencies




Equity:




Albemarle Corporation shareholders' equity:




Common stock

1,169



1,069


Additional paid-in capital

2,907,981



1,438,038


Accumulated other comprehensive loss

(328,001)



(326,132)


Retained earnings

3,584,400



3,155,252


Total Albemarle Corporation shareholders' equity

6,165,549



4,268,227


Noncontrolling interests

200,222



200,367


Total equity

6,365,771



4,468,594


Total liabilities and equity

$

10,796,926



$

10,450,946


 

Albemarle Corporation and Subsidiaries
Selected Consolidated Cash Flow Data
(In Thousands) (Unaudited)


Six Months Ended

June 30,


2021


2020

Cash and cash equivalents at beginning of year

$

746,724



$

613,110


Cash flows from operating activities:




Net income

563,906



227,393


Adjustments to reconcile net income to cash flows from operating activities:




Depreciation and amortization

123,683



111,535


Gain on sale of business

(429,408)




Stock-based compensation and other

8,425



9,765


Equity in net income of unconsolidated investments (net of tax)

(34,509)



(57,718)


Dividends received from unconsolidated investments and nonmarketable securities

27,420



12,984


Pension and postretirement benefit

(8,465)



(3,312)


Pension and postretirement contributions

(20,266)



(6,692)


Unrealized gain on investments in marketable securities

(2,384)



(1,278)


Loss on early extinguishment of debt

28,955




Deferred income taxes

27,708



8,990


Working capital changes

7,942



(156,579)


Non-cash transfer of 40% value of construction in progress of Kemerton plant to MRL

96,185



87,750


Other, net

(3,339)



(24,921)


Net cash provided by operating activities

385,853



207,917


Cash flows from investing activities:




Acquisitions, net of cash acquired



(22,572)


Capital expenditures

(396,915)



(418,991)


Cash proceeds from divestitures, net

290,467




Sales of marketable securities, net

4,553



1,496


Investments in equity and other corporate investments

(286)



(486)


Net cash used in investing activities

(102,181)



(440,553)


Cash flows from financing activities:




Proceeds from issuance of common stock

1,453,888




Repayments of long-term debt and credit agreements

(1,173,823)




Proceeds from borrowings of credit agreements



452,163


Other debt repayments, net

(325,316)



12,956


Fees related to early extinguishment of debt

(24,877)




Dividends paid to shareholders

(86,637)



(79,909)


Dividends paid to noncontrolling interests

(43,698)



(14,286)


Proceeds from exercise of stock options

14,335



10,809


Withholding taxes paid on stock-based compensation award distributions

(7,047)



(4,019)


Other

(1,359)



(2,669)


Net cash (used in) provided by financing activities

(194,534)



375,045


Net effect of foreign exchange on cash and cash equivalents

(12,290)



(18,823)


Increase in cash and cash equivalents

76,848



123,586


Cash and cash equivalents at end of period

$

823,572



$

736,696


 

Albemarle Corporation and Subsidiaries
Consolidated Summary of Segment Results
(In Thousands) (Unaudited)


Three Months Ended


Six Months Ended


June 30,


June 30,


2021


2020


2021


2020

Net sales:








Lithium

$

320,334



$

283,722



$

599,310



$

520,540


Bromine Specialties

279,748



232,779



560,195



464,371


Catalysts

148,344



197,053



368,587



404,260


All Other

25,470



50,495



75,095



113,723


Total net sales

$

773,896



$

764,049



$

1,603,187



$

1,502,894










Adjusted EBITDA:








Lithium

$

109,441



$

94,536



$

215,877



$

173,173


Bromine Specialties

92,646



73,041



187,286



156,303


Catalysts

21,164



22,777



46,591



70,247


All Other

8,379



18,598



29,858



41,422


Corporate

(37,002)



(23,759)



(54,930)



(59,587)


Total adjusted EBITDA

$

194,628



$

185,193



$

424,682



$

381,558


See accompanying non-GAAP reconciliations below.

Additional Information

It should be noted that adjusted net income attributable to Albemarle Corporation, adjusted diluted earnings per share, non-operating pension and OPEB items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These non-GAAP measures should not be considered as alternatives to Net income attributable to Albemarle Corporation ("earnings") or other comparable measures calculated and reported in accordance with GAAP. These measures are presented here to provide additional useful measurements to review the company's operations, provide transparency to investors and enable period-to-period comparability of financial performance. The company's chief operating decision maker uses these measures to assess the ongoing performance of the company and its segments, as well as for business and enterprise planning purposes.

A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also is available on Albemarle's website at https://investors.albemarle.com. The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.

ALBEMARLE CORPORATION AND SUBSIDIARIES
Non-GAAP Reconciliations
(Unaudited)

See below for a reconciliation of adjusted net income attributable to Albemarle Corporation, EBITDA and adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted earnings is defined as earnings before the non-recurring, other unusual and non-operating pension and other post-employment benefit (OPEB) items as listed below. The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges and other significant non-recurring items. EBITDA is defined as earnings before interest and financing expenses, income taxe expense, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA plus or minus the non-recurring, other unusual and non-operating pension and OPEB items as listed below.


Three Months Ended


Six Months Ended


June 30,


June 30,

In thousands, except percentages and per share amounts

2021


2020


2021


2020

Net income attributable to Albemarle Corporation

$

424,600



$

85,624



$

520,277



$

192,828


Add back:








Non-operating pension and OPEB items (net of tax)

(4,273)



(2,299)



(8,540)



(4,610)


Non-recurring and other unusual items (net of tax)

(315,996)



7,907



(283,235)



9,400


Adjusted net income attributable to Albemarle Corporation

$

104,331



$

91,232



$

228,502



$

197,618










Adjusted diluted earnings per share

$

0.89



$

0.86



$

1.98



$

1.86










Weighted-average common shares outstanding – diluted

117,436



106,535



115,383



106,524










Net income attributable to Albemarle Corporation

$

424,600



$

85,624



$

520,277



$

192,828


Add back:








Interest and financing expenses

7,152



17,852



51,034



34,737


Income tax expense

106,985



15,431



129,092



33,873


Depreciation and amortization

61,423



57,841



123,683



111,535


EBITDA

600,160



176,748



824,086



372,973


Non-operating pension and OPEB items

(5,471)



(2,895)



(10,936)



(5,803)


Non-recurring and other unusual items

(400,061)



11,340



(388,468)



14,388


Adjusted EBITDA

$

194,628



$

185,193



$

424,682



$

381,558










Net sales

$

773,896



$

764,049



$

1,603,187



$

1,502,894


EBITDA margin

77.6

%


23.1

%


51.4

%


24.8

%

Adjusted EBITDA margin

25.1

%


24.2

%


26.5

%


25.4

%

 

See below for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).


Lithium


Bromine
Specialties


Catalysts


Reportable
Segments
Total


All
Other


Corporate


Consolidated
Total


% of
Net
Sales

Three months ended June 30, 2021
















Net income (loss) attributable to Albemarle Corporation

$

74,593



$

80,148



$

8,446



$

163,187



$

7,972



$

253,441



$

424,600



54.9

%

Depreciation and amortization

33,497



12,498



12,718



58,713



407



2,303



61,423



7.9

%

Non-recurring and other unusual items

1,351







1,351





(401,412)



(400,061)



(51.7)

%

Interest and financing expenses











7,152



7,152



0.9

%

Income tax expense











106,985



106,985



13.8

%

Non-operating pension and OPEB items











(5,471)



(5,471)



(0.7)

%

Adjusted EBITDA

$

109,441



$

92,646



$

21,164



$

223,251



$

8,379



$

(37,002)



$

194,628



25.1

%

















Three months ended June 30, 2020
















Net income (loss) attributable to Albemarle Corporation

$

66,038



$

60,692



$

10,702



$

137,432



$

16,425



$

(68,233)



$

85,624



11.2

%

Depreciation and amortization

28,498



12,349



12,075



52,922



2,173



2,746



57,841



7.6

%

Non-recurring and other unusual items











11,340



11,340



1.5

%

Interest and financing expenses











17,852



17,852



2.3

%

Income tax expense











15,431



15,431



2.1

%

Non-operating pension and OPEB items











(2,895)



(2,895)



(0.4)

%

Adjusted EBITDA

$

94,536



$

73,041



$

22,777



$

190,354



$

18,598



$

(23,759)



$

185,193



24.2

%

















Six months ended June 30, 2021
















Net income (loss) attributable to Albemarle Corporation

$

144,965



$

162,261



$

21,362



$

328,588



$

27,988



$

163,701



$

520,277



32.5

%

Depreciation and amortization

65,303



25,025



25,229



115,557



1,870



6,256



123,683



7.7

%

Non-recurring and other unusual items

5,609







5,609





(394,077)



(388,468)



(24.2)

%

Interest and financing expenses











51,034



51,034



3.2

%

Income tax expense











129,092



129,092



8.1

%

Non-operating pension and OPEB items











(10,936)



(10,936)



(0.7)

%

Adjusted EBITDA

$

215,877



$

187,286



$

46,591



$

449,754



$

29,858



$

(54,930)



$

424,682



26.5

%

















Six months ended June 30, 2020
















Net income (loss) attributable to Albemarle Corporation

$

119,278



$

132,357



$

45,594



$

297,229



$

37,271



$

(141,672)



$

192,828



12.8

%

Depreciation and amortization

53,895



23,946



24,653



102,494



4,151



4,890



111,535



7.4

%

Non-recurring and other unusual items











14,388



14,388



1.0

%

Interest and financing expenses











34,737



34,737



2.3

%

Income tax expense











33,873



33,873



2.3

%

Non-operating pension and OPEB items











(5,803)



(5,803)



(0.4)

%

Adjusted EBITDA

$

173,173



$

156,303



$

70,247



$

399,723



$

41,422



$

(59,587)



$

381,558



25.4

%

 

Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other income (expenses), net. Non-operating pension and OPEB items were as follows (in thousands):


Three Months Ended


Six Months Ended


June 30,


June 30,


2021


2020


2021


2020

Interest cost

$

5,430



$

7,133



$

10,858



$

14,288


Expected return on assets

(10,901)



(10,028)



(21,794)



(20,091)


Total

$

(5,471)



$

(2,895)



$

(10,936)



$

(5,803)


 

In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):


Three Months Ended


Six Months Ended


June 30,


June 30,


2021


2020


2021


2020

Restructuring and other(1)

$



$

0.04



$

0.01



$

0.06


Acquisition and integration related costs(2)

0.01



0.04



0.03



0.06


Albemarle Foundation contribution(3)

0.13





0.13




Gain on sale of business(4)

(2.82)





(2.87)




Loss on early extinguishment of debt(5)

0.01





0.21




Other(6)

0.04



(0.01)



0.10



(0.02)


Discrete tax items(7)

(0.06)





(0.06)



(0.01)


Total non-recurring and other unusual items

$

(2.69)



$

0.07



$

(2.45)



$

0.09




(1)

During the three and six months ended June 30, 2021, Albemarle recorded facility closure costs related to offices in Germany, and severance expenses in Germany and Belgium, in Selling, general and administrative expenses of $0.8 million and $1.5 million ($0.5 million and $1.1 million after income taxes, or less than $0.01 and $0.01 per share), respectively. In 2020, Albemarle recorded severance expenses as part of business reorganization plans, impacting each of its businesses and Corporate, primarily in the U.S., Germany and with its Jordanian joint venture partner. During the three months ended June 30, 2020, the company recorded expenses of $6.7 million ($4.7 million after income taxes, or $0.04 per share) in Selling, general and administrative expenses. During the six months ended June, 2020, the company recorded severance expenses in Cost of goods sold, Selling, general and administrative expenses and Net income attributable to noncontrolling interest of $0.7 million, $8.2 million and a $0.3 million gain ($6.2 million after income taxes, or $0.06 per share), respectively. The balance of unpaid severance is recorded in Accrued expenses and is expected to primarily be paid through 2021.




(2)

Costs related to the acquisition, integration and potential divestitures of various significant projects, recorded in Selling, general and administrative expenses for the three and six months ended June 30, 2021 were $1.9 million and $4.1 million ($1.5 million and $3.2 million after income taxes, or $0.01 and $0.03 per share), respectively, and for the three and six months ended June 30, 2020 were $5.5 million and $8.4 million ($4.2 million and $6.5 million after income taxes, or $0.04 and $0.06 per share), respectively.




(3)

Included in Selling, general and administrative expenses for the three and six months ended June 30, 2021 is a charitable contribution of $20.0 million ($15.5 million after income taxes, or $0.13 per share), using a portion of the proceeds received from the FCS divestiture, to the Albemarle Foundation, a non-profit organization that sponsors grants, health and social projects, educational initiatives, disaster relief, matching gift programs, scholarships and other charitable initiatives in locations where Albemarle's employees live and the company operates. This contribution is in addition to the normal annual contribution made to the Albemarle Foundation by the company, and is significant in size and nature in that it is intended to provide more long-term benefits in these communities.




(4)

Included in Gain on sale of business, for the three and six months ended June 30, 2021 is $429.4 million ($331.6 million after discrete income taxes, or $2.87 per share) related to the sale of the FCS business.




(5)

Included in Interest and financing expenses for the three and six months ended June 30, 2021 is a loss on early extinguishment of debt of $1.2 million and $29.0 million ($0.8 million and $23.8 million after income taxes, or $0.01 and $0.21 per share), respectively, representing the tender premiums, fees, unamortized discounts and unamortized deferred financing costs from the redemption of $1.5 billion in debt using the proceeds from the issuance of common stock.




(6)

Other adjustments for the three months ended June 30, 2021 included amounts recorded in:


Selling, general and administrative expenses - $4.0 million of a loss resulting from the sale of property, plant and equipment, $1.6 million of charges for an environmental reserve at a site not part of the company's operations and $1.4 million of expenses primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements.


Other income, net - $0.3 million of a gain resulting from the adjustment of indemnification obligations related to previously disposed businesses.


After income taxes, these charges totaled $4.9 million, or $0.04 per share.




Other adjustments for the six months ended June 30, 2021 included amounts recorded in:


Selling, general and administrative expenses - $6.0 million of expenses primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements, a $4.0 million loss resulting from the sale of property, plant and equipment and $1.6 million of charges for an environmental reserve at a site not part of the company's operations.


Other income, net - $3.6 million of expenses primarily related to asset retirement obligation charges to update an estimate at a site formerly owned by Albemarle.


After income taxes, these charges totaled $11.4 million, or $0.10 per share.




Other adjustments for the three months ended June 30, 2020 included amounts recorded in:


Other expenses, net - $0.9 million ($0.6 million after income taxes, or $0.01 per share) net gain primarily relating to the sale of idle properties in Germany.




Other adjustments for the six months ended June 30, 2020 included amounts recorded in:


Other expenses, net - $2.7 million gain resulting from the settlement of a legal matter related to a business sold and $0.8 million net gain primarily relating to the sale of idle properties in Germany, partially offset by a $0.8 million loss resulting from the adjustment of indemnifications related to previously disposed businesses.


After income taxes, these net gains totaled $1.7 million, or $0.02 per share.



(7)

Included in Income tax expense for the three and six months ended June 30, 2021 are discrete net tax benefits of $7.6 million, or $0.06 per share and $6.6 million, or $0.06 per share, respectively. The net benefit for the three months is primarily related to excess tax benefits realized from stock-based compensation arrangements and the revaluation of deferred taxes due to tax rate changes. The net benefit for the six months is primarily related to the release of a foreign valuation allowance, excess tax benefits realized from stock-based compensation arrangements, and the revaluation of deferred taxes due to tax rate changes, partially offset by tax expense due to an out-of-period adjustment regarding an overstated deferred tax liability for the three-month period ended December 31, 2017.




Included in Income tax expense for the three and six months ended June 30, 2020 are discrete net tax benefits of $0.5 million, or less than $0.01 per share, and $1.6 million, or $0.01 per share. The net benefit for the three months is primarily related to lapses in statute of limitations. The net benefit for the six months is primarily related to excess tax benefits realized from stock-based compensation arrangements.

 

See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).


Income before
income taxes and
equity in net income
of unconsolidated
investments


Income tax
expense


Effective income
tax rate

Three months ended June 30, 2021






As reported

$

535,195



$

106,985



20.0

%

Non-recurring, other unusual and non-operating pension and OPEB items

(404,383)



(84,114)




As adjusted

$

130,812



$

22,871



17.5

%







Three months ended June 30, 2020






As reported

$

88,075



$

15,431



17.5

%

Non-recurring, other unusual and non-operating pension and OPEB items

8,445



2,837




As adjusted

$

96,520



$

18,268



18.9

%







Six months ended June 30, 2021






As reported

$

658,489



$

129,092



19.6

%

Non-recurring, other unusual and non-operating pension and OPEB items

(370,457)



(78,682)




As adjusted

$

288,032



$

50,410



17.5

%







Six months ended June 30, 2020






As reported

$

203,548



$

33,873



16.6

%

Non-recurring, other unusual and non-operating pension and OPEB items

8,906



3,795




As adjusted

$

212,454



$

37,668



17.7

%

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/albemarle-reports-second-quarter-results-301348671.html

SOURCE Albemarle Corporation

image